Bundelkhand Online Journal

Exatecan Mesylate: Proprietary ADC Payload Product Based on BOC Sciences cGMP Platform

 Breaking News
  • No posts were found

Exatecan Mesylate: Proprietary ADC Payload Product Based on BOC Sciences cGMP Platform

April 28
22:48 2021
BOC Sciences announced the release of its latest cytotoxic product-Exatecan Mesylate.

New York, USA – April 28, 2021 – BOC Sciences, a biotechnology company based on a proprietary small molecule and API synthesis technology platform, can provide cGMP-compliant payloads/cytotoxins for antibody-drug conjugates (ADC), and announced the release of its latest cytotoxic product: Exatecan Mesylate.

Exatecan Mesylate is a synthetic analog of CPT, which is synthesized to increase solubility and enhance anti-tumor efficacy. The anhydrous, alkali-free form of the drug is called DX-8951. In vitro studies have shown that Exatecan Mesylate is more active than SN-38 and Topotecan on cell lines of various types of human tumors (including breast cancer, lung cancer, gastric cancer, and colon cancer). In the human tumor cloning test, Exatecan Mesylatef showed a dose-dependent inhibitory effect on clonal cells from head and neck, liver, non-small cell lung cancer, breast cancer, colon cancer, ovarian cancer, and prostate cancer. Exatecan Mesylate also has broad activity in human tumor xenografts of breast, lung, gastric, pancreatic, esophageal, and colon cancer, CPT-11-resistant non-small cell lung cancer and pancreatic tumor implanted in nude mice.

Although Exatecan Mesylate has high potency and potential bystander lethality, so far, its relatively challenging biophysical properties may limit exploration in the ADC field. By combining Exatecan Mesylate with BOC Sciences’s high-affinity ADC conjugation technology, the polymerization problem can be solved, and a highly stable and efficient ADC can be obtained.

About BOC Sciences

BOC Sciences, a life science group headquartered in New York, provides the most complete solution for antibody-drug conjugate (ADC) drug development in the pharmaceutical industry. Years of successful operations in the pharmaceutical industry have enabled this company to have a complete antibody-drug conjugate service series. BOC Sciences provides customers with one-stop comprehensive services in all aspects of ADC research and evaluation, ranging from antibody modification and coupling, ADC payload development, payload linker synthesis, ADC coupling to ADC characterization and manufacturing. In addition, it also provides an extensive list of linkers, payloads, and payload linker sets.

For more details, please visit https://adc.bocsci.com.

Media Contact
Company Name: BOC Sciences
Contact Person: Alex Brown
Email: Send Email
Phone: 1-631-485-4226
Country: United States
Website: https://adc.bocsci.com


Warning: count(): Parameter must be an array or an object that implements Countable in /home/capitalnews/bundelkhandonlinejournal.in/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share